An increase in the systemic LPS level may enhance pain in diabetes and advance development of neuropathy, since LPS is a TRPA1 agonist and it enhances the effect of other TRPA1 agonists such as 4-hydroxynonenal, the concentration of which is increased in diabetes. The gene discussed is TRPA1; the disease is neuropathy.